Akums to acquire Oriflame India’s manufacturing assets for Rs 56 crore

Akums Drugs and Pharmaceuticals will acquire Oriflame India’s Roorkee and Noida factories plus a leased Noida warehouse, expanding into colour cosmetics alongside skincare, wellness and hair care manufacturing.

— Source publishedThu, 23 Jul, 2026, 19:17 IST·First seen Thu, 23 Jul, 2026, 19:37 IST·Source ET Small Business

What happened

Akums Drugs and Pharmaceuticals · Akums will acquire Oriflame India’s Roorkee and Noida manufacturing facilities and a Noida warehouse for Rs 56 crore, entering

Key facts

  • Rs 56 crore cash consideration
  • Two manufacturing facilities
  • One leased warehouse
  • Expected completion by August 31, 2026

Why this matters

This is a focused asset-led bolt-on that secures established Oriflame India facilities and expands Akums’ capabilities for Indian and global beauty-brand contracts.

What to watch

  • Completion of the deal by the targeted August 31, 2026 date and disclosure of final asset-transfer terms.
  • Any transition manufacturing, supply or services agreement between Akums and Oriflame India.
  • Plant capacity, current utilisation, employee-transfer details and incremental capex requirements.
  • New colour-cosmetics customer wins, especially from large Indian D2C brands, retailers or international beauty labels.
  • Management guidance on revenue contribution, EBITDA margin effect and integration costs.
  • Regulatory or quality-certification updates that determine the facilities' ability to serve export-oriented customers.
  • Changes in India’s colour-cosmetics demand, private-label activity and competitive pricing among CDMO manufacturers.
  • Retain technical, quality-control and plant leadership teams to preserve formulation and regulatory know-how.
  • Audit plant utilisation, machinery condition, product-category certifications and warehouse lease liabilities before final closing.
  • Package colour cosmetics with Akums' existing skincare, hair-care and wellness capabilities into end-to-end proposals for D2C brands, retailers and global beauty companies.
  • Prioritise customer qualification and regulatory validation for high-volume categories such as lip, face and eye cosmetics.
  • Use the acquired Noida footprint to shorten development-to-launch cycles for North India-focused beauty customers.
  • Assess whether to keep producing for Oriflame under a transitional supply arrangement or redeploy capacity to third-party clients.